{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.31","value":"33.71"},{"groupId":"OG001","spread":"52.48","value":"30.05"},{"groupId":"OG002","spread":"47.63","value":"31.96"},{"groupId":"OG003","spread":"44.54","value":"31.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib Vss/F Derived After Multiple Dose Administration","type":"SECONDARY","unitOfMeasure":"L"}